ARTICLE | Clinical News
Gilead preclinical data
October 24, 2016 7:00 AM UTC
In a mouse xenograft model of NSCLC, twice-daily 50 and 100 mg/kg oral ND-646 for 6 weeks significantly reduced total lung tumor burden by 80% and 82%, respectively, vs. vehicle-treated controls (p<0....